43
New ESC Guidelines for TAVI and transcatheter mitral valve repair Alec Vahanian University Paris VII,Paris ,France

New ESC Guidelines for TAVI and transcatheter mitral valve …Alec Vahanian University Paris VII,Paris ,France Recommandations in the ACC/AHA 2017 Update Mitral regurgitation Recommendations

  • Upload
    others

  • View
    3

  • Download
    0

Embed Size (px)

Citation preview

  • New ESC Guidelines for TAVI and transcatheter mitral valve repair

    Alec Vahanian

    University Paris VII,Paris ,France

  • Recommandations in the ACC/AHA 2017 Update

  • Mitral regurgitation

  • Recommendations in the ACC/AHA 2017 Update

  • 2017 ESC/EACTS Guidelines for the Management of Valvular Heart Disease (European Heart Journal 2017 - doi:10.1093/eurheartj/ehx391)

    )

    www.escardio.org/guidelines 29

    Recommendations Class Level

    When revascularization is not indicated and surgical risk is not low, a percutaneous edge-to-edge procedure may be considered in patients with severe secondary mitral regurgitation and LVEF >30% who remain symptomatic despite optimal medical management (including CRT if indicated) and who have a suitable valve morphology by echocardiography, avoiding futility.

    IIb C

    In patients with severe secondary mitral regurgitation and LVEF

  • Recommendations in ACC/AHA Valve Guidelines Update 2017

    “Percutaneous mitral valve repair provides a less

    invasive alternative to surgery but is not approved for

    clinical use for this indication in the United States .

    The results of RCTs examining the efficacy of

    percutaneous mitral valve repair in patients with

    secondary MR are needed to provide information on

    this patient group”

  • Conclusions

    The update of the ACC/AHA and the new ESC/EACTS Guidelines are consistent overall in recommending to enlarge the use of TAVI to intermediate risk patients after an evaluation by the “Heart team” based on an individualized approach

    The ESC Guidelines state that Mitra clip may be considered in selected high risk patients with primary or secondary MR while the ACC/AHA Guidelines limit the use of the device to primary MR

  • (Capodanno. EuroIntervention 2017)

  • Supplementary Data - pdf file Comments 0 Comments

    https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/38/36/10.1093_eurheartj_ehx391/2/VHD_Section_ehx391.pdf?Expires=1507478116&Signature=M7DxmsWBB4enkqKHjIsR8-nRfet9ZtYekL7ZkQ5mC1fGAlBAak-7~4ZeYK83LMGKzE1ZdW7MT6apbv~f~98QQhsqV3nkrLcMdqNBa3TZK5HI5cqUqVo9Vsa78J-ZWsxLTUlsOLx9ABEq2dKGlg6UKKz5dZkNzieyH5MLtlLy75SYL-WFfjTRZME7L-PPdbVC-AAWLrz9OlwY8bp8WvuYqfj4K3zRLA0nhQIofwXY9afTO8iRTLUD2C7D0VSW9lRUcAfB-~9xEwHXj36vBh5dyPiyUoThLThM9omK-r7233mEomEB33Uq3w6sdSqUzVnbziSU2i8~21TDDkI1zZiKfQ__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Qhttps://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/38/36/10.1093_eurheartj_ehx391/2/VHD_Section_ehx391.pdf?Expires=1507478116&Signature=M7DxmsWBB4enkqKHjIsR8-nRfet9ZtYekL7ZkQ5mC1fGAlBAak-7~4ZeYK83LMGKzE1ZdW7MT6apbv~f~98QQhsqV3nkrLcMdqNBa3TZK5HI5cqUqVo9Vsa78J-ZWsxLTUlsOLx9ABEq2dKGlg6UKKz5dZkNzieyH5MLtlLy75SYL-WFfjTRZME7L-PPdbVC-AAWLrz9OlwY8bp8WvuYqfj4K3zRLA0nhQIofwXY9afTO8iRTLUD2C7D0VSW9lRUcAfB-~9xEwHXj36vBh5dyPiyUoThLThM9omK-r7233mEomEB33Uq3w6sdSqUzVnbziSU2i8~21TDDkI1zZiKfQ__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Qhttps://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/38/36/10.1093_eurheartj_ehx391/2/VHD_Section_ehx391.pdf?Expires=1507478116&Signature=M7DxmsWBB4enkqKHjIsR8-nRfet9ZtYekL7ZkQ5mC1fGAlBAak-7~4ZeYK83LMGKzE1ZdW7MT6apbv~f~98QQhsqV3nkrLcMdqNBa3TZK5HI5cqUqVo9Vsa78J-ZWsxLTUlsOLx9ABEq2dKGlg6UKKz5dZkNzieyH5MLtlLy75SYL-WFfjTRZME7L-PPdbVC-AAWLrz9OlwY8bp8WvuYqfj4K3zRLA0nhQIofwXY9afTO8iRTLUD2C7D0VSW9lRUcAfB-~9xEwHXj36vBh5dyPiyUoThLThM9omK-r7233mEomEB33Uq3w6sdSqUzVnbziSU2i8~21TDDkI1zZiKfQ__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Qhttps://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/38/36/10.1093_eurheartj_ehx391/2/VHD_Section_ehx391.pdf?Expires=1507478116&Signature=M7DxmsWBB4enkqKHjIsR8-nRfet9ZtYekL7ZkQ5mC1fGAlBAak-7~4ZeYK83LMGKzE1ZdW7MT6apbv~f~98QQhsqV3nkrLcMdqNBa3TZK5HI5cqUqVo9Vsa78J-ZWsxLTUlsOLx9ABEq2dKGlg6UKKz5dZkNzieyH5MLtlLy75SYL-WFfjTRZME7L-PPdbVC-AAWLrz9OlwY8bp8WvuYqfj4K3zRLA0nhQIofwXY9afTO8iRTLUD2C7D0VSW9lRUcAfB-~9xEwHXj36vBh5dyPiyUoThLThM9omK-r7233mEomEB33Uq3w6sdSqUzVnbziSU2i8~21TDDkI1zZiKfQ__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q

  • Thank You

  • Choice between TAVR and SAVR in the patient with severe symptomatic AS